Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Profitability
This table compares Petros Pharmaceuticals and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Petros Pharmaceuticals | N/A | -78.22% | -23.50% |
| Whitehawk Therapeutics | N/A | -79.63% | -74.01% |
Analyst Recommendations
This is a summary of current ratings and price targets for Petros Pharmaceuticals and Whitehawk Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Petros Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| Whitehawk Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Valuation and Earnings
This table compares Petros Pharmaceuticals and Whitehawk Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Petros Pharmaceuticals | $5.11 million | 0.04 | -$8.16 million | ($1.64) | 0.00 |
| Whitehawk Therapeutics | $7.14 million | 29.23 | -$20.60 million | ($1.68) | -2.51 |
Petros Pharmaceuticals has higher earnings, but lower revenue than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Petros Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Institutional & Insider Ownership
12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Whitehawk Therapeutics beats Petros Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
